Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 7Sarcoma 4Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

Radiotherapy 64Temozolomide 59Vincristine 33Cyclophosphamide 32Carboplatin 30Radiosurgery 26Etoposide 25Cisplatin 25Lomustine 24Magnetic Resonance Spectroscopy 19Filgrastim 17Doxorubicin 15Bevacizumab 15Radiation 13Specimen Handling 12Granulocyte Colony-Stimulating Factor 12Surgical Procedures, Operative 11Isotretinoin 11Melphalan 10Carmustine 10Procarbazine 9Platinum 9Peripheral Blood Stem Cell Transplantation 9Chemotherapy, Adjuvant 9etoposide phosphate 7Topotecan 71,2-diaminocyclohexaneplatinum II citrate 7sargramostim 6Thiotepa 6Radiotherapy, Intensity-Modulated 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Dexrazoxane × CNS × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡